CLINICAL TRIALS PROFILE FOR VEGZELMA

All Clinical Trials for VEGZELMA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04919629 ↗	APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion	Recruiting	National Cancer Institute (NCI)	Phase 2	2023-02-17	This phase II trial studies the effect of APL-2 when given in combination with either pembrolizumab or pembrolizumab and bevacizumab compared with bevacizumab alone in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent) and a buildup of fluid and cancer cells (malignant effusion). APL-2 may limit tumor progression, decrease malignant effusion production, and improve the immune system's response against cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving APL-2 together with either pembrolizumab or pembrolizumab and bevacizumab may work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer and malignant effusion compared to bevacizumab alone.
NCT04919629 ↗	APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion	Recruiting	Roswell Park Cancer Institute	Phase 2	2023-02-17	This phase II trial studies the effect of APL-2 when given in combination with either pembrolizumab or pembrolizumab and bevacizumab compared with bevacizumab alone in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent) and a buildup of fluid and cancer cells (malignant effusion). APL-2 may limit tumor progression, decrease malignant effusion production, and improve the immune system's response against cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Giving APL-2 together with either pembrolizumab or pembrolizumab and bevacizumab may work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer and malignant effusion compared to bevacizumab alone.
NCT06047379 ↗	Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis	Recruiting	Neonc Technologies, Inc.	Phase 1/Phase 2	2023-11-01	This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled brain metastasis. The study will have three phases, Phase 1, Phase 2a and Phase 2b.

Clinical Trial Conditions for VEGZELMA

Condition Name

Condition Name for VEGZELMA
Intervention	Trials
Fallopian Tube Clear Cell Adenocarcinoma	1
Mismatch Repair Deficient Colorectal Cancer	1
Recurrent Fallopian Tube Carcinoma	1
Fallopian Tube Endometrioid Adenocarcinoma	1

Condition MeSH

Condition MeSH for VEGZELMA
Intervention	Trials
Carcinoma	2
Brain Neoplasms	1
Lung Neoplasms	1
Astrocytoma	1

Clinical Trial Locations for VEGZELMA

Trials by Country

Trials by Country for VEGZELMA
Location	Trials
United States	3

Trials by US State

Trials by US State for VEGZELMA
Location	Trials
Washington	1
California	1
New York	1

Clinical Trial Progress for VEGZELMA

Clinical Trial Phase

Clinical Trial Phase for VEGZELMA
Clinical Trial Phase	Trials
Phase 2	1
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for VEGZELMA
Clinical Trial Phase	Trials
Recruiting	2

Clinical Trial Sponsors for VEGZELMA

Sponsor Name

Sponsor Name for VEGZELMA
Sponsor	Trials
National Cancer Institute (NCI)	1
Roswell Park Cancer Institute	1
Neonc Technologies, Inc.	1

Sponsor Type

Sponsor Type for VEGZELMA
Sponsor	Trials
NIH	1
Other	1
Industry	1

Last updated: May 1, 2026

VEGZELMA (anti-VEGFR or VEGF-pathway agent): clinical trials update and market outlook

No reliable, complete, source-backed record of a drug named VEGZELMA with identifiable mechanism of action, sponsor, trial identifiers, trial phases, sites/territories, safety or efficacy outcomes, or commercial launch status is available in the information provided here. Without those anchor facts, a clinical trials update and market analysis for VEGZELMA cannot be produced in a way that meets high-stakes patent, investment, and R&D decision standards.

What is VEGZELMA in the clinical pipeline?

No verifiable, source-backed identity (INN/brand-to-molecule mapping) is provided for VEGZELMA, so the drug’s:

• Target class (VEGFR vs VEGF ligand vs biosimilar vs combo)
• Indication(s) under evaluation
• Trial phases and progression dates
• Primary endpoints and outcome readouts cannot be stated.

Which trials have reported results for VEGZELMA?

No trial-level identifiers (e.g., NCT/CTRI/EudraCT), enrollment sizes, arm structures, or reported results are provided for VEGZELMA. A “clinical trials update” requires at least one of:

• trial registry entries with endpoints and results
• press releases with date-stamped efficacy/safety data
• peer-reviewed publications linked to specific trials

None are available here.

How does VEGZELMA compete in its market?

A market analysis requires:

• the approved indication (or the intended label)
• the pricing and reimbursement context
• the competitive set in that same indication and line of therapy
• the addressable patient population and adoption drivers

No indication, approval status, or dosing form factor is provided for VEGZELMA, so competitive positioning cannot be computed.

Market projection: what adoption curve and revenue pathway apply to VEGZELMA?

A defensible projection needs:

• launch year and geographies
• forecast model assumptions (penetration, persistence, switching, sequencing)
• capacity constraints (if biologic) and access constraints
• patent and exclusivity timelines that shape peak sales

No launch timing, regulatory status, or exclusivity/patent situation is provided for VEGZELMA, so a projection cannot be produced.

What does the evidence say for near-term value?

No evidence set is available to support:

• probability-weighted clinical timelines
• risk-adjusted valuation inputs
• a scenario analysis tied to readouts

Key Takeaways

• A clinical trials update and market projection for VEGZELMA cannot be generated from the information provided.
• No verifiable mapping from the brand name VEGZELMA to a specific molecular entity, trial program, or commercial status is available here.
• Without those anchors, any claims about efficacy, safety, trial progression, or market size would not meet decision-grade standards.

FAQs

1. Is VEGZELMA an FDA-approved product?
   Not determinable from the information provided.

2. What is VEGZELMA’s mechanism of action?
   Not determinable from the information provided.

3. Which clinical trials (NCT/EudraCT) cover VEGZELMA?
   Not determinable from the information provided.

4. What indications are in VEGZELMA’s development program?
   Not determinable from the information provided.

5. How would VEGZELMA’s revenue forecast be modeled?
   It requires indication, approval status, sponsor strategy, trial outcomes, and competitive set, which are not provided here.

---

References (APA)

No sources were provided or verifiable in the information available in this chat.